Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
Status:
Completed
Trial end date:
2017-05-05
Target enrollment:
Participant gender:
Summary
RATIONALE: Midostaurin may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Midostaurin may help azacitidine kill more cancer cells by making the cancer cells
more sensitive to the drug. PURPOSE: This phase I/II trial is studying the side effects and
best dose of midostaurin when given together with azacitidine and to see how well it works in
treating elderly patients with acute myelogenous leukemia.